How Stapley was paid
$7.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Marc StapleyChief Executive Officer | $700,000 | $5,890,877 | $826,000 | $5,000 | $7,421,877 |
| Rebecca ChambersChief Financial Officer | $550,000 | $1,963,604 | $356,950 | $5,000 | $2,875,554 |
| Phillip FebboChief Scientific Officer and Chief Medical Officer | $561,000 | $1,570,883 | $364,089 | $5,000 | $2,500,972 |
| John LeiteGlobal Chief Commercial Officer | $510,300 | $2,356,325 | $331,185 | $5,000 | $3,202,810 |
| Annie McGuireGeneral Counsel and Head of Market Access | $500,000 | $1,963,604 | $324,500 | $5,000 | $2,793,104 |
What changed and why
- $517.1MTotal revenue grew 16% over 2024 to $517.1 million driven primarily by Decipher and Afirma products.
- $66.4MNet income increased 175% over 2024 to $66.4 million through disciplined financial and budget management.
- 118%Annual cash incentive metrics for testing revenue and adjusted EBITDA margin were achieved at 118%.
- 50%NEO equity awards consisted of 50% performance stock units and 50% restricted stock units.
- 97.3%Stockholders supported the 2025 say-on-pay proposal with approximately 97.3% of votes cast in favor.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.